Poliovirus Vaccine Market Report 2025 (Global Edition)

Global Poliovirus Vaccine Market Report 2024 Market Size Split by Type (Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV))), by End Users (Hospitals, Homecare, Specialty Clinics, Others), by A...

Poliovirus Vaccine Market Report Description

We have various report editions of Poliovirus Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Poliovirus Vaccine Market Insights Video

Competitive Landscape of the Poliovirus Vaccine Market

A competitive landscape with major competitors, including Sanofi Pasteur, GSK, Serum Institute of India, and Bharat Biotech, characterizes the poliovirus vaccine market. These businesses concentrate on developing new products, refining vaccine formulas, and increasing production capacities. Governments and international health organizations work together to improve accessibility and distribution. Businesses are investing in cutting-edge production processes and research in order to stay relevant in the market as the move toward inactivated poliovirus vaccines, or IPVs gathers steam.

In January 2024, the United Nations Children's Fund (UNICEF) donated 340,000 oral polio vaccine (OPV) pills to Ukraine in support of the country's National Immunization Program, protecting children against a potentially fatal virus. The US Agency for International Development (USAID) provided assistance for this effort. (Source: https://www.unicef.org/ukraine/en/press-releases/unicef-delivers-oral-polio-vaccine) In March 2021 and September 2020, Sanofi S.A.'s Canadian manufacturing facility announced that it would invest over 600 million euros in the development of new vaccines. This will benefit the company's product range and portfolio. (Source:https://www.sanofi.com/en/media-room/press-releases/2021/2021-03-31-14-05-00-2202566) In September 2020, Sanofi Pasteur India announced the launch of Tetraxim (DTaP-IPV), a booster vaccine that protects against tetanus, pertussis, diphtheria, and polio and is advised for preschool-aged children. (Source:https://www.sanofi.in/dam/jcr:c7dd91d8-d5ad-4e6e-9e71-6b7c6661ae37/sanofi_pasteur_launches_tetraxim.pdf)

Top Companies Market Share in Poliovirus Vaccine Industry: (In no particular order of Rank)

• Pfizer Inc. (U.S.)
• Mylan N.V. (U.S.)
• Sanofi (France)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co.
• Inc. (U.S.)
• Serum Institute of India Pvt. Ltd (India)
• BIO-MED (India)
• Astellas Pharma Inc. (Japan)
• HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Poliovirus Vaccine Market

Which Region Dominates the Poliovirus Vaccine Market in 2024?

According to Cognitive Market Research, North America currently dominates the Poliovirus Vaccine market, and the region is expected to have significant growth during the projected period. Because of its robust public health system and extensive immunization programs, North America is well-positioned to propel the growth of the poliovirus vaccine market. Governmental entities like as the Centers for Disease Control and Prevention (CDC) and other non-governmental organizations provide significant funds to support the region's efforts to eradicate polio. Vaccination efforts are improved by stronger surveillance and quick response mechanisms, in addition to heightened knowledge of the significance of vaccines. North America is positioned as a leader in global polio immunization campaigns and market expansion because of continued research and development of new vaccines, such as the Inactivated Poliovirus Vaccine (IPV), which ensures high safety and efficacy requirements.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Due to continuous public health activities aimed at eradicating polio, the Asia Pacific region is expected to fuel the growth of the poliovirus vaccine market significantly. Numerous immunization efforts have been backed by groups like the World Health Organization (WHO) and GAVI in response to the ongoing poliovirus challenges in countries like India and Pakistan. Expanded immunization coverage is facilitated by more healthcare spending, better cold chain management, and increased public knowledge of the advantages of vaccinations. Furthermore, local production capabilities are making vaccines more accessible, guaranteeing prompt delivery, and ultimately driving market growth in this vast and diverse region.

The current report Scope analyzes Poliovirus Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Poliovirus Vaccine

According to Cognitive Market Research, the global Poliovirus Vaccine market size was estimated at USD 821.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 328.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Poliovirus Vaccine market with a market size of USD 259.17 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. The United States boasts a highly developed healthcare infrastructure and an extensive immunization program that encourages routine immunizations, including those against the poliovirus.
• The Canada Poliovirus Vaccine market had a market share of USD 39.42 million in 2024 and is projected to grow at a CAGR of 4.2% during the forecast period. The demand for poliovirus vaccination is fueled by Canada's emphasis on preventative healthcare, which includes immunization requirements for admission to institutions.
• The Mexico Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 29.89 million in 2024.

Europe Poliovirus Vaccine

According to Cognitive Market Research, the global Poliovirus Vaccine market size was estimated at USD 821.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 246.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.

• The United Kingdom Poliovirus Vaccine market had a market share of USD 41.39 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. In the UK, Because the NHS offers free vaccinations, more people will receive them, which will increase immunization rates.
• The France Poliovirus Vaccine market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 22.67 million in 2024.
• According to Cognitive Market Research, the German Poliovirus Vaccine market size was valued at USD 48.78 million in 2024 and is projected to grow at a CAGR of 3.9% during the forecast period. In Germany, research and immunization campaigns are aided by collaborations with international health organizations.
• The Italy Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.1% during the forecast period, with a market size of USD 21.19 million in 2024.
• The Russia Poliovirus Vaccine market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 38.19 million in 2024.
• The Spain Poliovirus Vaccine market is projected to witness growth at a CAGR of 2.8% during the forecast period with a market size of USD 20.20 million in 2024
• The Luxembourg Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 7.64 million in 2024.
• The Portugal Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 5.17 million in 2024.
• The Greece Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 2.96 million in 2024.
• The Rest of Europe's Poliovirus Vaccine market is projected to witness growth at a CAGR of 2.4% during the forecast period, with a market size of USD 38.19 million in 2024.

Asia Pacific Poliovirus Vaccine

According to Cognitive Market Research, the global Poliovirus Vaccine market size was estimated at USD 821.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 188.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Poliovirus Vaccine market size was valued at USD 84.99 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. Poliovirus Vaccine sales surged in China because China's government strongly encourages vaccination by funding numerous public health campaigns and providing children with free vaccines.
• The Japan Poliovirus Vaccine market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 26.06 million in 2024.
• The India Poliovirus Vaccine market had a market share of USD 22.67 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. In India, In both rural and urban regions, vaccination uptake has improved in response to initiatives to eradicate polio.
• The South Korean Poliovirus Vaccine market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 18.89 million in 2024.
• The Australian Poliovirus Vaccine market is projected to witness growth at a CAGR of 6.9% during the forecast period, with a market size of USD 9.82 million in 2024.
• The South East Asia Poliovirus Vaccine market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 13.03 million in 2024.
• The Rest of Asia Pacific Poliovirus Vaccine market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 13.41 million in 2024.

South America Poliovirus Vaccine

According to Cognitive Market Research, the global Poliovirus Vaccine market size was estimated at USD 821.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 41.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Poliovirus Vaccine market size was valued at USD 17.57 million in 2024 and is projected to grow at a CAGR of 5.2% during the forecast period. Poliovirus Vaccines flourished in Brazil because Brazil's participation in global health programs encourages vaccination accessibility and highlights the significance of polio eradication.
• Argentina's Poliovirus Vaccine market had a market share of USD 6.90 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. In Argentina, healthcare professionals' capacity to promote immunizations is strengthened by ongoing education.
• Colombia Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.4% during the forecast period, with a market size of USD 3.65 million in 2024.
• Peru Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 3.37 million in 2024.
• Chile's Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 2.96 million in 2024.
• The Rest of Latin America's Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 6.61 million in 2024.

Middle East and Africa Poliovirus Vaccine

According to Cognitive Market Research, the global Poliovirus Vaccine market size was estimated at USD 821.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 16.42 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031..

• The GCC Countries Poliovirus Vaccine market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 7.03 million in 2024. Poliovirus vaccine sales flourish in GCC countries because the GCC emphasizes public health by offering vaccines widely and implementing extensive immunization programs.
• The Egypt Poliovirus Vaccine market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 1.72 million in 2024.
• The South African poliovirus Vaccine market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 2.59 million in 2024. Poliovirus Vaccine sales flourished in South Africa due to pediatric healthcare professionals being essential in encouraging immunizations for children.
• The Turkey Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.4% during the forecast period, with a market size of USD 1.41 million in 2024.
• The Nigeria Poliovirus Vaccine market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 1.72 million in 2024.
• The Rest of the MEA Poliovirus Vaccine market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 1.94 million in 2024.

Poliovirus Vaccine Market Analysis

Poliovirus Vaccine Market Type Segment Analysis

According to Cognitive Market Research, oral polio vaccine (OPV)) are likely to dominate the Poliovirus Vaccine Market over the forecast period. The market for poliovirus vaccines still has a sizable demand for oral polio vaccines (OPV), especially in underdeveloped nations where polio is still widespread. For mass vaccination efforts, OPV is the recommended option due to its simplicity of administration and capacity to create herd immunity. Its affordable price and efficient oral delivery also aid in its broad distribution, particularly in places with little healthcare infrastructure. Global health groups continue to support OPV for quick outbreak responses despite worries about vaccine-derived poliovirus, maintaining its demand and bolstering efforts to eradicate polio.

Inactivated polio vaccine (IPV) is the fastest-growing segment in the Poliovirus Vaccine Market. In the market for poliovirus vaccines, there is a growing need for inactivated polio vaccine (IPV), especially as nations move toward safer vaccination alternatives. Because IPV removes the possibility of poliovirus derived from vaccines, it has a greater safety profile and is therefore favored. Particularly in areas shifting from the oral polio vaccine (OPV), governments and health organizations are introducing IPV into regular immunization schedules. IPV is becoming more and more popular despite being more expensive and requiring skilled workers to administer, especially in wealthy countries and areas where polio is still a threat due to its ability to provide long-lasting immunity.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Poliovirus Vaccine Industry. Request a Free Sample PDF!

Poliovirus Vaccine Market End Users Segment Analysis

According to Cognitive Market Research, the hospital segment holds the largest share of the market. Hospitals are important end-users in the market for poliovirus vaccines since they are the main locations where polio vaccinations, especially the inactivated polio vaccine (IPV), are administered. Hospitals enable the effective execution of vaccination programs, guaranteeing patient safety and effective immunization, thanks to their well-established infrastructure and skilled medical staff. They are essential to both the regular children's immunization program and the attempts to contain outbreaks. Hospital participation in immunization programs is being driven by increased awareness of polio eradication and healthcare investments, which is improving overall coverage and greatly boosting the market's growth.

In the Poliovirus Vaccine Market, the category of specialty clinics has been growing quickly. Specialty clinics, which concentrate on providing focused immunization services for particular populations, such as babies and high-risk groups, are important end users in the poliovirus vaccine market. These clinics guarantee that patients obtain the recommended vaccines in accordance with health guidelines by providing individualized treatment and education. They play a crucial role in the administration of the inactivated polio vaccine (IPV), especially in areas with limited access to conventional healthcare facilities. Specialty clinic demand is being driven by the increased focus on vaccine awareness and preventative healthcare, which is helping to improve vaccination rates and support international efforts to eradicate polio.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Poliovirus Vaccine Application Segment Analysis

Poliovirus Vaccine Market Application Segment Analysis

According to Cognitive Market Research, the public segment holds the largest market share. The public's usage of the poliovirus vaccine market is necessary for the broad immunization against polio, especially for community health initiatives. Governments and health organizations plan mass immunization campaigns at community centers, schools, and public health events with the specific goal of targeting vulnerable people. These programs aim to boost herd immunity and halt outbreaks, particularly in endemic areas. Public health awareness campaigns promote involvement by teaching communities about the importance of immunizations. The dedication to accomplishing worldwide polio eradication highlights the critical function that public applications play in advancing vaccine accessibility and coverage.

Private is anticipated to be the fastest-growing segment in the Poliovirus Vaccine market. The use of private clinics and healthcare professionals to deliver polio vaccinations, especially for regular immunization regimens, is known as the "private application of the Poliovirus Vaccine Market." These establishments frequently provide more individualized assistance to families looking to vaccinate their children on time. Partnerships between public and private organizations can also be formed for outreach initiatives, particularly in regions with less access to public health care. Increased knowledge of the value of vaccinations, parental worries about polio, and a growing need for personalized healthcare services are the main drivers of the demand for polio vaccines in private settings.

• Public
• Private

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion